Fig. 4: Lenalidomide and bortezomib enhanced VIS832-induced MM cell lysis in a synergistic manner. | Blood Cancer Journal

Fig. 4: Lenalidomide and bortezomib enhanced VIS832-induced MM cell lysis in a synergistic manner.

From: VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo

Fig. 4

Indicated MM cell lines (a, b MM1S, MM1R; c, d RPMI8226, H929) were pretreated without (a, c) or with lenalidomide (len, b) or bortezomib (btz, d), and then drugs were washed out. Target MM cells were co-incubated with NK cells (E:T = 4:1) in the presence of varying concentrations of VIS832 or control media (ctrl) in the 2-h calcein-AM release assay. a, c VIS832 was added together with Len (a) or btz (c) in the co-cultures of target MM cells with NK cells. Percentages of MM cell lysis were used to calculate the combination index (CI) (Fa-CI plot) shown below each graph. CI < 1 indicated a synergistic interaction. Fa, fraction affected. All assays included three independent experiments using NK cells from 3 healthy donors. Data are presented as means (% lysis) ± SDs (error bars). *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001.

Back to article page